BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36730386)

  • 1. Atypical Molecular Features of Pediatric Tectal Glioma: A Single Institutional Series.
    Yakir MJ; Elster JD; Paul MR; Khanna PC; Malicki DM; Levy ML; Crawford JR
    J Pediatr Hematol Oncol; 2023 Apr; 45(3):e410-e414. PubMed ID: 36730386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations.
    Chiang J; Li X; Liu APY; Qaddoumi I; Acharya S; Ellison DW
    Acta Neuropathol; 2020 Mar; 139(3):601-602. PubMed ID: 31822998
    [No Abstract]   [Full Text] [Related]  

  • 3. IDH-mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature.
    Chang EK; Smith-Cohn MA; Tamrazi B; Ji J; Krieger M; Holdhoff M; Eberhart CG; Margol AS; Cotter JA
    Brain Pathol; 2021 Jul; 31(4):e12959. PubMed ID: 33960568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel KRAS mutation in an unusual tectal low-grade glioma.
    Wulfovich S; Tucker S; Levy M; Crawford JR
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33795262
    [No Abstract]   [Full Text] [Related]  

  • 5. Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas.
    Schittenhelm J; Krischker N; Gepfner-Tuma I; Behling F; Noell S; Eckert F; Biskup S; Tabatabai G
    Brain Pathol; 2019 May; 29(3):321-324. PubMed ID: 30676672
    [No Abstract]   [Full Text] [Related]  

  • 6. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
    Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
    J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    Li Y; Liu B; Connolly ID; Kakusa BW; Pan W; Nagpal S; Montgomery SB; Hayden Gephart M
    J Thorac Oncol; 2018 Jul; 13(7):1022-1027. PubMed ID: 29604399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
    Villalva C; Duranton-Tanneur V; Guilloteau K; Burel-Vandenbos F; Wager M; Doyen J; Levillain PM; Fontaine D; Blons H; Pedeutour F; Karayan-Tapon L
    Cancer Med; 2013 Jun; 2(3):296-304. PubMed ID: 23930206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
    BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
    Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P
    Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Mutation in Pediatric Intracranial Germ Cell Tumors.
    Khaiman C; Techavichit P; Poparn H; Chiangthong K; Lauhasurayotin S; Sosothikul D; Shotelersuk K; Nantavithya C; Jakchairoongruang K; Amornfa J; Khongkhaduead E; Santisukwongchote S; Teerapakpinyo C; Shuangshot S
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):3179-3185. PubMed ID: 36172682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
    Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
    Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial ND5 mutations mimicking brainstem tectal glioma.
    Rio M; Lebre AS; de Lonlay P; Valayannopoulos V; Desguerre I; Dufier JL; Grévent D; Zilbovicius M; Tréguier C; Brunelle F; de Baracé C; Kaplan J; Espinase-Berrod MA; Sainte-Rose C; Puget S; Rotig A; Munnich A; Boddaert N
    Neurology; 2010 Jul; 75(1):93. PubMed ID: 20603491
    [No Abstract]   [Full Text] [Related]  

  • 19. Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis.
    Rau KM; Chen HK; Shiu LY; Chao TL; Lo YP; Wang CC; Lin MC; Huang CC
    Int J Mol Sci; 2016 Apr; 17(4):524. PubMed ID: 27070580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.